ID   Ma-Mel-08a
AC   CVCL_A121
SY   Ma-Mel-8a; MaMel-08a; MaMel08a
DR   cancercelllines; CVCL_A121
DR   Cosmic; 1467738
DR   Cosmic; 1846566
DR   Cosmic; 2163818
DR   Cosmic; 2686330
DR   ECACC; 13012434
DR   ESTDAB; ESTDAB-105
DR   GEO; GSM436989
DR   Progenetix; CVCL_A121
DR   Wikidata; Q54903730
RX   PubMed=17311103;
RX   PubMed=20544847;
RX   PubMed=23348503;
RX   PubMed=23851445;
RX   PubMed=26909863;
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Gene fusion; HGNC; HGNC:7413; MTAP + HGNC; HGNC:34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Glu157Ter (c.469G>T); ClinVar=VCV000007814; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Asp162Val (c.485A>T); Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg283Cys (c.847C>T); ClinVar=VCV000127824; Zygosity=Unspecified (PubMed=23851445).
CC   Omics: SNP array analysis.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
CC   Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
ST   Source(s): ECACC=13012434; ESTDAB=ESTDAB-105
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 9,13
ST   D3S1358: 14,15
ST   D5S818: 12,13
ST   D7S820: 10
ST   FGA: 21
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C4225; Cutaneous nodular melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A122 ! Ma-Mel-08b
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 21
//
RX   PubMed=17311103; DOI=10.1371/journal.pone.0000236; PMCID=PMC1794595;
RA   Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A.,
RA   Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R.,
RA   Schadendorf D.;
RT   "B-RAF and N-RAS mutations are preserved during short time in vitro
RT   propagation and differentially impact prognosis.";
RL   PLoS ONE 2:E236-E236(2007).
//
RX   PubMed=20544847; DOI=10.1002/gcc.20785;
RA   Gast A., Scherer D., Chen B.-W., Bloethner S., Melchert S., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Somatic alterations in the melanoma genome: a high-resolution
RT   array-based comparative genomic hybridization study.";
RL   Genes Chromosomes Cancer 49:733-745(2010).
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=26909863; DOI=10.18632/oncotarget.7503; PMCID=PMC4941330;
RA   Xie H.-P., Rachakonda P.S., Heidenreich B., Nagore E., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Mapping of deletion breakpoints at the CDKN2A locus in melanoma:
RT   detection of MTAP-ANRIL fusion transcripts.";
RL   Oncotarget 7:16490-16504(2016).
//